MMW - Fortschritte der Medizin

, Volume 160, Issue 7, pp 52–62 | Cite as

Häufige Rhythmusstörungen in der hausärztlichen Praxis

Herzen ohne Takt — das ist zu tun!

FORTBILDUNG . ÜBERSICHT
First Online:

Zusammenfassung

Patienten mit Herzrhythmusstörungen sind eine besondere Herausforderung für den Hausarzt. Er muss erkennen, ob die Arrhythmien harmlos oder gefährlich sind, aber in der Regel sind die Phasen von Herzklopfen, Herzjagen oder Schwindel zum Zeitpunkt der Vorstellung beim Hausarzt oder während der Untersuchung schon nicht mehr nachweisbar. In diesem Beitrag geben wir für die häufigsten Rhythmusstörungen Tipps zur Diagnosesicherung.

Heart rhythm disturbances in family doctor’s practice

Keywords

Bradycardia premature ventricular beats atrial fibrillation and flutter antiarrhythmic drugs ablation 
This is a preview of subscription content, log in to check access

Literatur

  1. 1.
    Brignole M, Auricchio A, Baron-Esquivias G et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–329CrossRefGoogle Scholar
  2. 2.
    Kostis JB, McCrone K, Moreyra AE et al. Premature ventricular complexes in the absence of identifiable heart disease. Circulation. 1981;63:1351–6CrossRefGoogle Scholar
  3. 3.
    Pedersen CT, Kay GN, Kalman J et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace. 2014;16:1257–83CrossRefGoogle Scholar
  4. 4.
    Bogun F, Crawford T, Reich S et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. 2007;4:863–7CrossRefGoogle Scholar
  5. 5.
    Gopinathannair-Retheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol. 2015;66:1714–28CrossRefGoogle Scholar
  6. 6.
    Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867CrossRefGoogle Scholar
  7. 7.
    Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962CrossRefGoogle Scholar
  8. 8.
    Motloch LJ, Reda S, Larbig R et al. Characteristics of coronary artery disease among patients with atrial fibrillation compared to patients with sinus rhythm. Hellenic J Cardiol. 2017;58:204–12CrossRefGoogle Scholar
  9. 9.
    Botto GL, Padeletti L, Santini M et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol. 2009;20:241–8CrossRefGoogle Scholar
  10. 10.
    Mairesse GH, Moran P, Van Gelder IC et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). Europace. 2017;19:1589–623CrossRefGoogle Scholar
  11. 11.
    Doherty JU, Gluckman TJ, Hucker WJ et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69:871–98CrossRefGoogle Scholar
  12. 12.
    Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S–50S.CrossRefGoogle Scholar
  13. 13.
    Hoffmeister HM, Bode C. Positionspapier Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen. Der Kardiologe. 2010;4:365–74CrossRefGoogle Scholar
  14. 14.
    Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016;388:818–28CrossRefGoogle Scholar
  15. 15.
    Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417–27CrossRefGoogle Scholar
  16. 16.
    Estner HL, Zviman MM, Herzka D et al. The critical isthmus sites of ischemic ventricular tachycardia are in zones of tissue heterogeneity, visualized by magnetic resonance imaging. Heart Rhythm. 2011;8:1942–9CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.LMU Klinikum der Universität MünchenMünchenDeutschland
  2. 2.Ludwig-Maximilians-UniversitätMünchenDeutschland

Personalised recommendations